Goldstein F W, Acar J F
Laboratoire de Microbiologie Médicale, Fondation Hôpital Saint-Joseph, Paris, France.
Drugs. 1995;49 Suppl 2:36-42. doi: 10.2165/00003495-199500492-00007.
After nearly 10 years of fluoroquinolone usage for a wide range of bacterial infections, a striking difference has been observed in the incidence of bacterial resistance to fluoroquinolones between bacteria responsible for community- and hospital-acquired infections, respectively. Resistance is only rarely encountered among common pathogens. In most studies, 97 to 100% of all pathogens are fully susceptible to fluoroquinolones. In contrast, resistance to fluoroquinolones has emerged and increased among bacteria responsible for nosocomial infections. The incidence of resistance to fluoroquinolones varies between bacterial species, clinical settings and countries, and is related to local epidemic spread of a few clones. The highest incidence of resistance is observed in Pseudomonas aeruginosa, Acinetobacter spp., Serratia marcescens and, particularly, methicillin-resistant Staphylococcus aureus (MRSA): some investigators have reported 95 to 100% fluoroquinolone resistance among MRSA. Follow-up of trends in the resistance to fluoroquinolones based upon surveillance programmes are needed.
在氟喹诺酮类药物用于治疗多种细菌感染近10年后,已观察到社区获得性感染和医院获得性感染的病原菌对氟喹诺酮类药物的耐药率存在显著差异。在常见病原体中,耐药情况很少见。在大多数研究中,所有病原体中有97%至100%对氟喹诺酮类药物完全敏感。相比之下,医院感染病原菌中对氟喹诺酮类药物的耐药情况已出现并有所增加。对氟喹诺酮类药物的耐药率因细菌种类、临床环境和国家而异,并且与少数克隆株的局部流行传播有关。在铜绿假单胞菌、不动杆菌属、粘质沙雷氏菌,尤其是耐甲氧西林金黄色葡萄球菌(MRSA)中观察到最高的耐药率:一些研究人员报告称,MRSA中对氟喹诺酮类药物的耐药率为95%至100%。需要基于监测计划对氟喹诺酮类药物耐药趋势进行跟踪。